leucrose: RN given refers to all (D)-isomer
leucrose : A glycosylfructose consisting of an alpha-D-glucopyranosyl residue joined to D-fructopyranose via a (1->5)-linkage. An isomer of sucrose.
ID Source | ID |
---|---|
PubMed CID | 165577 |
SCHEMBL ID | 3832014 |
MeSH ID | M0168140 |
Synonym |
---|
leucrose |
4B42CA92-416A-4C2C-BAAA-D31AD7F77B1F |
d-glucopyranosyl-alpha(1-5)-d-fructopyranose |
unii-yac4299isi |
d-fructose, 5-o-alpha-d-glucopyranosyl- |
yac4299isi , |
d-fructose, 5-o-.alpha.-d-glucopyranosyl- |
470-16-6 |
5-o-.alpha.-d-glucopyranosyl-d-fructose |
SCHEMBL3832014 |
n2-[n2-(1-l-threonyl-l-prolyl)-l-arginyl]-l-lysine diacetate salt |
W-203595 |
(3s,4s,5r)-1,3,4,6-tetrahydroxy-5-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]oxy-hexan-2-one |
(3s,4s,5r)-5-[(2r,3r,4s,5s,6r)-6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-1,3,4,6-tetrakis(oxidanyl)hexan-2-one |
Q3237106 |
DXALOGXSFLZLLN-WTZPKTTFSA-N |
DTXSID40992132 |
5-o-hexopyranosylhex-2-ulose |
(3s,4s,5r)-1,3,4,6-tetrahydroxy-5-(((2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)hexan-2-one |
F81529 |
AKOS040752512 |
Leucrose is a novel noncariogenic disaccharide. It represents a highly promising sugar substitute for caries prevention.
Excerpt | Reference | Relevance |
---|---|---|
"Leucrose is a novel noncariogenic disaccharide and thus represents a highly promising sugar substitute for caries prevention." | ( Cariological assessment of leucrose [D-glucopyranosyl-alpha(1----5)-D-fructopyranose] as a sugar substitute. Imfeld, T; Siebert, G; Ziesenitz, SC, 1989) | 1.3 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (13.04) | 18.7374 |
1990's | 8 (34.78) | 18.2507 |
2000's | 10 (43.48) | 29.6817 |
2010's | 2 (8.70) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (28.61) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (4.17%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 23 (95.83%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |